SEC Form 4 · accession 0001209191-18-034229
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles G Phillips III
Director
Period of report
May 25, 2017
Accepted (ET)
May 30, 2018 · 6:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | May 25, 2018 | M | 50,000 | $6.72 | A | 50,000 | D | |
| Ordinary SharesF1 | May 25, 2018 | S | 50,000 | $30.3015 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF2 | $6.72 | May 25, 2018 | M | 50,000 | A | — | Sep 28, 2022 | Ordinary Shares | 50,000 | 112,607 | D |
Explanation of responses
- F1On May 25, 2018, Mr. Phillips sold 50,000 shares in multiple trades at prices ranging from $30.125 to $30.625. The price reported above reflects the weighted average sale price. Mr. Phillips hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F2Options to buy 50,000 ordinary shares are vested and currently exercisable as of the date hereof.